Shots:

• The approval is based on P-II L-MIND study assessing Monjuvi in combination with lenalidomide as a treatment for adult patients with relapsed or refractory DLBCL
• Results: ORR (55%); CR (37%); PR (18%); mDOR (21.7mos.). Additionally- the US FDA has granted BT designation for the combination therapy for r/r DLBCL
• Monjuvi is a humanized Fc-modified cytolytic CD19 targeting mAb- has been approved under US FDA’s accelerated approval- and is expected to be commercially available in the US. MorphoSys and Incyte will co-commercialize Monjuvi in the US & has exclusive commercialization rights outside the territory

­ Ref: MorphoSys | Image: StraitTimes